IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 599.00, up by 6.40 points or 1.08% from its previous closing of Rs. 592.60 on the BSE.

The scrip opened at Rs. 595.90 and has touched a high and low of Rs. 611.60 and Rs. 593.55 respectively. So far 70137 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.30 on 12-May-2021 and a 52 week low of Rs. 356.20 on 01-Jun-2020.

Last one week high and low of the scrip stood at Rs. 614.90 and Rs. 578.65 respectively. The current market cap of the company is Rs. 16721.28 crore.

The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 35.00% and 18.38% respectively.

Glenmark Pharmaceuticals has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai, Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on May 16, 2016.

According to IQVIA sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million. Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.